Marked Chart Marked Chart Closed

The Marked Chart Wire · Series of events

Series of events · Sanofi

Sanofi lifts outlook and wins new drug approval

Sanofi beat earnings estimates and raised its 2026 forecast before European regulators approved its new rabies vaccine.

3 eventsOct 30 to Nov 19SNY-2.2%

Updated

The flow in 3 points

  1. Sanofi beat quarterly revenue and profit forecasts
  2. Full year 2026 guidance was raised
  3. European Commission approved VaxRabeo for all ages

What happened, in order

Times are Eastern
  1. Where it began

    Earnings beat

    Sanofi reported quarterly results that exceeded analyst forecasts for revenue and profit, then raised its full year 2026 guidance.

    Read the story
  2. Forecast boost

    The company raised its annual profit target, citing solid performance from its top-selling drug Dupixent.

    Read the story
  3. Latest

    Rabies shot cleared

    The European Commission granted approval for VaxRabeo to be administered to patients of any age.

    Read the story

How they connect

Sanofi first reported strong quarterly results and raised its 2026 outlook, then detailed that Dupixent performance supported the higher profit target. Later, European regulators approved the company's new rabies vaccine.

The stocks in this series

  1. SNY-2.2%Sanofi$46.06

Prices from Based on Thu, Nov 19 close · Opens Fri 9:30 AM ET. Each tile opens the stock's chart and news.

A series is a short summary of connected news, for learning. Not verified and not advice. Check the full stories before you act.